Mind Cure Announces Geoff Belair as Chief Technology Officer
This news release is not for distribution to U.S. newswire services for dissemination in the United States.
Vancouver, BC – October 15, 2020 – Mind Cure Health Inc. (CSE:MCUR) (“Mind Cure” or the “Corporation”), is pleased today to announce the hiring of Geoff Belair as the company's new Chief Technology Officer. Mr. Belair brings with him to Mind Cure a wealth of technology leadership experience in the highly regulated industries of fintech and insurance. He will lead the management and operations of Mind Cure's internal technology processes, team and the integration and development of future technology platforms.
"Mr. Belair is the right person at the right moment for Mind Cure as we build up our internal business operation processes and develop our own innovative technologies for the market," said Philip Tapley, Chairman, President, and CEO. "In particular, his experience building and managing complex technology systems in highly regulated environments will be key as we work to establish Mind Cure as a leader in the mental health treatment revolution that is underway."
Mind Cure's leadership team believes that technology is going to play a key role in the future of this industry, from a research and development standpoint to the associated treatments and therapies with doctors and patients. As Mind Cure's Chief Technology Officer, Mr. Belair will lead all efforts to ensure that Mind Cure is making the most effective investments and developments related to its internal processes and external technology platform.
"I am thrilled to join Mr. Tapley and the world class team at Mind Cure," said Geoff Belair. "I have spent the majority of my career in highly regulated industries and know the importance of building trust and security into all facets of technological teams and operations. Technology can have a significant impact on how mental health is treated, and I look forward to driving Mind Cure's mission forward through effective technology utilization."
About Geoff Belair
With over 30 years of experience in the fintech industry, Mr. Belair has built innovative and industry-leading technology solutions to drive operations forward. He possesses a unique combination of software architecture and design experience with a deep understanding of technology adoption and change management.
By leading and empowering multidisciplinary teams throughout his career, he has delivered ground-breaking and innovative solutions throughout the fintech industry. As a senior architect and creator of the Integration Services Team with Fincentric Corporation, a banking solutions company, he led successful implementations at Stanford University's Bank in Palo Alto California and American Express Bank in Singapore. Most recently, he served as Vice President of Information Technology at Westland Insurance.
The Company has granted a total of 200,000 stock options to Mr. Belair pursuant to the terms of his executive employment agreement and the Company's incentive stock option plan (the "Plan"). The stock options are exercisable at a price of $0.79 and subject to the terms of the Plan.
About Mind Cure Health Inc.
Mind Cure is a mental health and wellness company with a mission to identify, develop and commercialize products that ease suffering, increase productivity, and enhance mental health. It is the therapeutic potential of nootropics, psychoactive products, and psychedelic substances to treat the profound distress of a world suffering from a mental health crisis that led to the formation of Mind Cure.
On behalf of the Board of Directors
Philip Tapley, Chairman, President, and CEO
Phone: +1 888 593-8995
Mind Cure Health Inc.
About this Press Release:
In Germany this press release is brought to you by Cannabisaktien.news – your German news platform for international cannabis stocks. For more information visit http://www.akt.ie/can-news
Certain statements in this news release may constitute "forward-looking information" within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "feel", "intend", "may", "plan", "predict", "project", "subject to", "will", "would", and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: the timing of the resumption of trading of common shares on the CSE and the trading symbol of the Shares on the CSE.
Forward-looking information is based on a number of key expectations and assumptions made by Mind Cure, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and Mind Cure's business, and the extent and duration of such impact; no material change will occur before trading resumes on the CSE; no change to laws or regulations that negatively affect Mind Cure's business; there will be a demand for Mind Cure's products in the future; and Mind Cure will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.
Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, Mind Cure's industry and Mind Cure's business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect Mind Cure's investments, results of operations, financial condition and Mind Cure's ability to obtain additional equity or debt financing, and satisfy its financial obligations; the ability for Mind Cure's common shares to resume trading on the CSE; general economic conditions; future growth potential; common share prices; liquidity; tax risk; tax laws currently in effect remaining unchanged; ability to access capital markets; competition for mental health and wellness investments; environmental matters; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under "Risk Factors" in the Prospectus which is available on SEDAR at www.sedar.com.
The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management's current beliefs and is based on information currently available to Mind Cure. The forward-looking information is stated as of the date of this news release and Mind Cure assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.
United States Advisory
The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), may be offered and sold outside the United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.
The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.
Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:
Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt.